Content
92%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
Well-structured, highly actionable content: decision frameworks, checkpoints, and executable script commands dominate, with details correctly pushed to one-level-deep reference files that all exist. The one weakness is inline time-sensitive material (FY2024 fees, dated QMSR-transition details) that would be better isolated or deferred to a reference with a verify-current note.
Suggestions
Move the FY2024 fee figures into references/fda_submission_guide.md and keep only the MDUFA verify-current pointer in SKILL.md.
Add the missing inline 'Reference:' pointer from the CAPA section to references/fda_capa_requirements.md, matching the pattern used by the other four sections.
Consider condensing the QMSR transition callout to the essential rule (ISO 13485:2016 incorporated by reference; legacy 820.x numbers are historical) and moving the full clause-mapping rationale into references/qsr_compliance_requirements.md.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The body is dense and lean — tables, decision trees, and checklists with almost no explanation of concepts Claude already knows. It loses a point for time-sensitive material inline: FY2024 user fees and the QMSR transition date (2026-02-02) appear in the main body rather than being quarantined in a dedicated old-patterns/deprecated section, though the legacy-QSR content is at least explicitly framed as historical ('Legacy QSR numbers below are kept only as a familiar index'). | 4 / 5 |
Actionability | Guidance is concrete and executable throughout: specific CFR/ISO citations, a pathway decision tree, required-section and RTA-issue tables keyed to 21 CFR 807.87, and copy-paste-ready script invocations ('python scripts/qsr_compliance_checker.py /path/to/project --section 820.30'). Specific examples cover the common cases (510(k) tracking, QMS checks, HIPAA technical safeguards). | 5 / 5 |
Workflow Clarity | Multi-step processes are clearly sequenced with explicit checkpoints: the 510(k) workflow embeds 'Checkpoint: SE argument feasible?' / 'Verification: SE letter received?' per phase, the design-controls workflow has a verification gate at each of six steps, and CAPA and HIPAA risk assessment are numbered step lists. No destructive or batch operations are involved, so no validation cap applies. | 5 / 5 |
Progressive Disclosure | The body is a genuine overview with one-level-deep references, each clearly signaled at the end of its section ('See [fda_submission_guide.md](references/fda_submission_guide.md) for pathway decision matrices'), plus a Resources section enumerating all scripts and reference files with purpose descriptions. All referenced paths exist in the bundle (5 references/, 3 scripts/), and the TOC makes navigation easy. | 5 / 5 |
Total | 19 / 20 Passed |